HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: The lipoprotein investigators collaborative

European Heart Journal

Volumn 36, Issue 1, 2015, Pages 22-30

  Martin, Seth S ^a   Khokhar, Arif A ^b   May, Heidi T ^c   Kulkarni, Krishnaji R ^d   Blaha, Michael J ^a   Joshi, Parag H ^a   Toth, Peter P ^a,e,f   Muhlestein, Joseph B ^c   Anderson, Jeffrey L ^c   Knight, Stacey ^c   Li, Yan ^g   Spertus, John A ^g   Jones, Steven R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c INTERMOUNTAIN MEDICAL CENTER   (United States)

^d Atherotech Diagnostics Inc   (United States)

^e CGH MEDICAL CENTER   (United States)

^f UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^g UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Acute myocardial infarction; Coronary heart disease; HDL subclasses; HDL2; HDL3; High density lipoprotein cholesterol; Lipids; Mortality; Secondary prevention

Indexed keywords

HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL FEATURE; DENSITY GRADIENT CENTRIFUGATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; CLASSIFICATION; CORONARY DISEASE; ISOLATION AND PURIFICATION; META ANALYSIS; MYOCARDIAL INFARCTION; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; ULTRACENTRIFUGATION;

AGED; CHOLESTEROL, HDL; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SECONDARY PREVENTION; ULTRACENTRIFUGATION;

EID: 84926389606     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu264     Document Type: Article

References (34)

1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiologic update. Eur Heart J 2013; 34: 3028-3034.
2. Gillespie CD, Wigington C, Hong Y. Centers for Disease Control and Prevention (CDC). Coronary heart disease and stroke deaths-United States, 2009.MMWR Surveill Summ 2013; 62(Suppl. 3): 157-160.
3. Toth PP. Pharmacomodulation of high-density lipoprotein metabolism as a therapeutic intervention for atherosclerotic disease. Curr Cardiol Rep 2010; 12: 481-487.
4. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'AgostinoRB Sr, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 2013; 7: 484-525.
5. Assmann G, Gotto AM. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004; 109: III8-III14.
6. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29: 870-876.
7. Angeloni E, Paneni F, Landmesser U, Benedetto U, Melina G, Lüscher TF, Volpe M, Sinatra R, Cosentino F. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J 2013; 34: 3557-3562.
8. Silbernagel G, Schöttker B, Appelbaum S, Scharnagl H, Kleber ME, Grammer TB, Ritsch A, Mons U, Holleczek B, Goliasch G, Niessner A, Boehm BO, Schnabel RB, Brenner H, Blankenberg S, Landmesser U, März W. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J 2013; 34: 3563-3571.
9. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L. Cholesterol efflux and atheroprotection: Advancing the concept of reverse cholesterol transport. Circulation 2012; 125: 1905-1919.
10. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991; 84: 129-139.
11. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997; 17: 1098-1105.
12. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. Aprospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.NEngl JMed 1991; 325: 373-381.
13. Sweetnam PM, Bolton CH, Yarnell JW, Bainton D, Baker IA, Elwood PC, Miller NE. Associations of theHDL2andHDL3cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation 1994; 90: 769-774.
14. Yu S, Yarnell JW, Sweetnam P, Bolton CH. High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis 2003; 166: 331-338.
15. Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, Armitage J, Collins R. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012; 125: 2469-2478.
16. Arnold SV, Chan PS, Jones PG, Decker C, Buchanan DM, Krumholz HM, Ho PM, Spertus JA. Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health status (TRIUMPH): Design and rationale of a prospective multicenter registry. Circ Cardiovasc Qual Outcomes 2011; 4: 467-476.
17. Taylor GS, Muhlestein JB, Wagner GS, Bair TL, Li P, Anderson JL. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J 1998; 136: 792-803.
18. Kulkarni KR. Cholesterol profile measurement by Vertical Auto Profile method. Clin Lab Med 2006; 26: 787-802.
19. Kulkarni KR, Garber DW, Marcovina SM, Segrest JP. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994; 35: 159-168.
20. Kulkarni KR, Marcovina SM, Krauss RM, Garber DW, Glasscock AM, Segrest JP. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. J Lipid Res 1997; 38: 2353-2364.
21. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994; 40: 586-592.
22. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): A case-control study. Lancet 2008; 372: 224-233.
23. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966; 34: 679-697.
24. Landmesser U, von Eckardstein A, Kastelein J, Deanfield J, Lüscher TF. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Eur Heart J 2012; 33: 1712-1715.
25. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebocontrolled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-1291.
26. Williams PT. Lowhigh-density lipoprotein3 reduces the odds ofmensurviving to age 85 during 53-year follow-up. J Am Geriatr Soc 2012; 60: 430-436.
27. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol 2008; 51: 49-55.
28. Stensvold I, Urdal P, Thurmer H, Tverdal A, Lund-Larsen PG, Foss OP. High-density lipoprotein cholesterol and coronary, cardiovascular and all cause mortality among middle-Aged Norwegian men and women. Eur Heart J 1992; 13: 1155-1163.
29. Paunio M, Heinonen OP, Virtamo J, Klag MJ, Manninen V, Albanes D, Comstock GW. HDL cholesterol and mortality in Finnish men with special reference to alcohol intake. Circulation 1994; 90: 2909-2918.
30. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-324.
31. Charakida M, Masi S, Deanfield JE. The Year in Cardiology 2012: focus on cardiovascular disease prevention. Eur Heart J 2013; 34: 314-317.
32. Rizzo M, Otvos JD, Nikolic D, Montalto G, Toth PP, Banach M. Subfractions and subpopulations of HDL: An update. Curr Med Chem 2014 [Epub ahead of print].
33. Toth PP, Barylski M, Nikolic D, Rizzo M, Montalto G, Banach M. Should low highdensity lipoprotein cholesterol (HDL-C) be treated? Best Pract Res Clin Endocrinol Metab 2014; 28: 353-368.
34. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D. ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.